[1] |
GUO Ningzi, LIU Li, YUE Ruiqi, FENG Huiqing, YANG Huaxin, WEI Ningyi, CHEN Hua.
Determination of particle size distribution of chiglitazar sodium by laser diffraction method
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 147-151.
|
[2] |
ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie.
Adverse reaction monitoring of toothpaste in China under the new regulatory system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
|
[3] |
ZHANG Bing, SA Rina, ZHANG Xiaomeng, ZHANG Dan, LIN Zhijian, WANG Yu.
Research progress in pharmacogenic cardiotoxicity
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 841-847.
|
[4] |
YANG Le, XIA Dongsheng, WANG Tao.
Risks to safety of vitamin B6 injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 791-794.
|
[5] |
MENG Kangkang, LIU Saiyue.
After-marketing safety of coenzyme Q10 for injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 795-798.
|
[6] |
.
Annual report of national adverse drug reaction monitoring (2022)
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 712-719.
|
[7] |
ZHU Lan, JIN Zhe, LIU Lihong, ZHONG Lumiao, LIUXiaojun.
Risks of Kangfuxiaoyan suppository due to routes of administration
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 306-310.
|
[8] |
YANG Le, XIA Dongsheng, WANG Tao.
Risks to safety of vitamin B2 injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1256-1258.
|
[9] |
LIU Cuili, WU Chen, WANG Tao.
Risks posed by misoprostol tablets used in obstetrics and gynecology
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 999-1001.
|
[10] |
MENG Kangkang, WANG Chunting, XIONG Weiyi.
Safety of propranolol tablets for infantile hemangioma
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 749-751.
|
[11] |
WU Chen, LIU Cuili, WANG Tao.
Cardiovascular safety of haloperidol preparations
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1100-1102.
|
[12] |
ZHAO Xuan, GUO Jing, REN Shuang, ZHEN Jiancun.
Management and working modes of outpatient pharmacies amid routine COVID-19 epidemic prevention
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 100-102.
|
[13] |
YU Yi, HUANG Qianqian, XIAO Aili.
Analysis of Safety Risks of Ginkgo Biloba Tablets and Other Oral Preparations
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 678-682.
|
[14] |
ZHAO Yan, ZHAO Yifei△, ZHENG Lijia, DONG Fang.
Medical Device Vigilance Systems in European Union
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 566-569.
|
[15] |
DENG Xia, LIU Bo, WANG Yuanzheng, YIN Xiao, SU Yao, ZHANG Yan, LI Yingli, GAO Chenyan, YANG Huan, WANG Tao.
Antibody-Dependent Enhancement of Vaccines and Development of Coronavirus Vaccines
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(3): 201-205.
|